Blog

FDA Grants Breakthrough Therapy Designation for Tezepelumab for Severe Asthma

AstraZeneca and its partner Amgen Inc. (Amgen) announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma, without an eosinophilic phenotype, who are receiving inhaled corticosteroids/long-acting beta2-agonists with or without oral corticosteroids and additional asthma controllers.

Aetna Decides FeNO Testing Is Medically Necessary for Its Members With Asthma

Circassia Pharmaceuticals, Inc., a specialty pharmaceutical company focused on respiratory disease, is pleased to announce that Aetna, one of the largest health insurance companies in the United States, has updated its Exhaled Breath Tests Clinical Policy to include the measurement of exhaled nitric oxide as “medically necessary” for the evaluation of asthma and for monitoring the response to long-term control therapy.

AAFA Applauds Walgreens and Kaléo Partnership, Increasing Patient Access to Life-Saving Epinephrine

Walgreens and kaléo, a privately-held pharmaceutical company, are working together to improve access to epinephrine auto-injectors by making kaléo’s AUVI-Q® available through Walgreens locations nationwide. The Asthma and Allergy Foundation of America (AAFA) applauds this effort to help thousands of Americans with their epinephrine needs during the back to school season, as supply issues have been reported to the U.S. Food and Drug Administration (FDA) by other manufacturers.

Walgreens Locations Will Now Carry AUVI-Q Epinephrine Auto-Injectors

Walgreens and kaléo, a privately-held pharmaceutical company, are working together to improve access to epinephrine auto-injectors by making kaléo’s AUVI-Q® 0.15 mg and 0.3 mg available through Walgreens locations nationwide. This comes in an effort to help thousands of Americans with their epinephrine needs during the back to school season, as supply issues have been reported to the U.S. Food and Drug Administration (FDA) by other manufacturers.

Asthma Medication Recall Alert: Montelukast Tablets From Camber Pharmaceuticals for Incorrect Drug in Bottle

The U.S. Food and Drug Administration is warning consumers and health care professionals about a voluntary recall of one lot of Montelukast Sodium Tablets – lot number MON17384, expiration 12/31/2019 – by Camber Pharmaceuticals, Inc., Piscataway, N.J. Sealed bottles labeled as montelukast sodium tablets, 10 milligram, 30-count bottle from Camber were found to instead contain 90 tablets of Losartan Potassium Tablets, 50 mg.

Plea to the Department of Health and Human Services: People With Allergies Need Access to Epinephrine Now

Manufacturing and insurance issues have made it hard for many members of our community to fill their prescriptions for epinephrine auto-injectors in recent months. But the drug epinephrine itself is not in short supply. This has become a serious concern for families of children with life-threatening food allergies. When families who manage food allergies are in fear for their children's lives because they can't get the medicine they need, our system is broken.

The Tools You Need to Send Your Child With Asthma Back to School

It’s time for a new school year, which means it’s time to make sure you have everything in place to help your child with asthma have a safe and successful year. As you gather book bags, lunch boxes and supplies for the new school year, check out these resources from the Asthma and Allergy Foundation of America (AAFA). We have helpful forms, free downloads and information on keeping your child healthy.

Ten Health and Medical Groups Oppose EPA's Harmful Clean Power Plan 'Replacement' Proposal

The Asthma and Allergy Foundation of America is sharing this press release to bring you the latest research news quickly. [PRESS RELEASE] Ten Health and Medical Groups Oppose EPA's Harmful Clean Power Plan 'Replacement' Proposal (August 22, 2018) - WASHINGTON, D.C. In response to the U.S. Environmental Protection Agency's (EPA) release of the proposed Affordable Clean Energy (ACE) rule to replace the Clean Power Plan, the Allergy & Asthma Network, the Alliance of Nurses for Healthy...

×
×
×
×